RxDoctor Payments Data

Kaitlin Spikes

Optometrist · Fayetteville, ARNPI 1992232235

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 26.4% of the total. Among optometrist clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,335in general payments, 2019–2025

Across 67 payments — averaging $34.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$615
  • Biotissue Holdings Inc.$308
  • AbbVie$271
  • Glaukos Corporation$218
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$171
  • Alcon$128
  • plus $623 from 10 others

What the payments were for

  • Food & beverage$2,335100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,335 in reported general payments places this provider in the 90th percentile of 442 optometrist providers in Arkansas.

See all optometrist providers in Arkansas

Medicare billing

Part B allowed, 2024
$109,182
Medicare patients
629
Services billed
1,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine16$14,418
Fluorometholone26$1,580
Latanoprost120$1,203
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha46$503
Timolol Maleate62$319
Prednisolone Acetate11$314
Ofloxacin14$192
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$139
Brimonidine Tartrate18$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$271$14,41816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 optometrist providers in Arkansas.

Other optometrist in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →